Horizons in Cancer Research. Volume 72

$250.00

Hiroto S. Watanabe (Editor)

Series: Horizons in Cancer Research
BISAC: MED062000

The first chapter of Horizons in Cancer Research. Volume 72 discusses the Ewing’s sarcoma family of tumors, including classic Ewing’s sarcoma of the bone, extraskeletal Ewing’s sarcoma and malignant peripheral primitive neuroectodermal tumor of both bone and soft tissue.

The following chapter discusses Primary Ewing’s sarcoma of the base of the tongue, particularly its diagnosis and treatment.

Additionally, the authors examine dual proteasome and histone deacetylase6 inhibitor, dual MDM2 and histone deacetylase inhibitor, and dual bromodomain-containing protein 4 and histone deacetylase inhibitor.

The authors go on to examine the genes and proteins involved in mitosis that are proposed as candidates for biomarkers in different types of cancer (colon, lung, prostate, breast and ovarian, among others).

The penultimate chapter reviews the published evidence of aromatase inhibitors in breast cancer risk reduction.  The recommended patient populations for the use of aromatase inhibitors, expected benefits, adverse effects and monitoring parameters are addressed.
The transcription factor and chromatin structure-related aspects of cancer treatment are the focus of the final chapter.

(Imprint: Nova Medicine and Health)

Table of Contents

Table of Contents

Preface

Chapter 1. Ewing Sarcoma Family of Tumors: Causes, Diagnosis and Treatment
(Pietro Abita, MD, Francesco Galletti, Bruno Galletti, Rocco Bruno, Francesco Martines, Francesco Dispenza, MD, Francesco Freni, and Federico Sireci, MD, Department of Otorhinolaryngology, University of Messina, Italy, and others)

Chapter 2. Diagnosis and Treatment of Ewing’s Sarcoma of the Tongue
(Pietro Abita, MD, Francesco Galletti, Bruno Galletti, Rocco Bruno, Francesco Martines, Frank Rikki Canevari, Francesco Dispenza, MD, Francesco Freni, and Federico Sireci, MD, Department of Otorhinolaryngology, University of Messina, Italy, and others)

Chapter 3. Histone Deacetylase Inhibitors in the Treatment of Hematological Malignancies
(Ota Fuchs, Institute of Hematology and Blood Transfusion, Prague, Czech Republic)

Chapter 4. Mitosis Targets as Biomarkers in Cancer
(Ana María Espinosa García, Unidad de Medicina Genómica, Hospital General de México, Delegación Cuauhtémoc, Ciudad de México

Chapter 5. Current Status of Aromatase Inhibitors for Breast Cancer Risk Reduction
(Jacqueline L. Olin, and Melani A. Rudisill, Wingate University School of Pharmacy, Wingate, North Carolina, and Novant Health Forsyth Medical Center, Winston Salem, North Carolina)

Chapter 6. Transcription Factors and Co-Activators/Co-Repressors of Transcription: Structure-Related Cancer Treatment
(Еlena А. Shestakova, PhD, Еlena К. Shematorova, PhD, Yuri V. Doludin, and George V. Shpakovski, PhD, Federal State Budgetary Institution “N.N. Blokhin National Medical Research Center of Oncology” of the Ministry of Health of the Russian Federation, Moscow, Russian Federation, and others)
Index

Publish with Nova Science Publishers

We publish over 800 titles annually by leading researchers from around the world. Submit a Book Proposal Now!